PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15474986-2	2005	To elucidate the cellular response to 4-NQO, we studied the transcriptional regulation of human proliferating cell nuclear antigen (hPCNA), an essential protein in DNA replication and repair, after 4-NQO treatment.	4-Nitroquinoline-1-oxide	38-43	proliferating cell nuclear antigen	Homo sapiens	96-130	
15474986-2	2005	To elucidate the cellular response to 4-NQO, we studied the transcriptional regulation of human proliferating cell nuclear antigen (hPCNA), an essential protein in DNA replication and repair, after 4-NQO treatment.	4-Nitroquinoline-1-oxide	38-43	proliferating cell nuclear antigen	Homo sapiens	132-137	
15474986-2	2005	To elucidate the cellular response to 4-NQO, we studied the transcriptional regulation of human proliferating cell nuclear antigen (hPCNA), an essential protein in DNA replication and repair, after 4-NQO treatment.	4-Nitroquinoline-1-oxide	198-203	proliferating cell nuclear antigen	Homo sapiens	96-130	
15474986-2	2005	To elucidate the cellular response to 4-NQO, we studied the transcriptional regulation of human proliferating cell nuclear antigen (hPCNA), an essential protein in DNA replication and repair, after 4-NQO treatment.	4-Nitroquinoline-1-oxide	198-203	proliferating cell nuclear antigen	Homo sapiens	132-137	
15474986-3	2005	We found that hPCNA promoter was dose-dependently transactivated by 4-NQO under the concentration of 2 microM via a previously reported p53-binding element located from -236 to -217 upstream of the transcription start site.	4-Nitroquinoline-1-oxide	68-73	proliferating cell nuclear antigen	Homo sapiens	14-19	
15474986-5	2005	It was observed that Staurosporine, a Ser/Thr kinase inhibitor, blocked the Ser15 phosphorylation of p53 and the hPCNA promoter response to 4-NQO simultaneously, suggesting that Ser15 phosphorylated p53 was the 4-NQO-responsive hPCNA regulator.	4-Nitroquinoline-1-oxide	140-145	proliferating cell nuclear antigen	Homo sapiens	113-118	
15474986-5	2005	It was observed that Staurosporine, a Ser/Thr kinase inhibitor, blocked the Ser15 phosphorylation of p53 and the hPCNA promoter response to 4-NQO simultaneously, suggesting that Ser15 phosphorylated p53 was the 4-NQO-responsive hPCNA regulator.	4-Nitroquinoline-1-oxide	211-216	proliferating cell nuclear antigen	Homo sapiens	113-118	
15474986-6	2005	The [3H]-thymidine deoxyribose (TdR) incorporation assay and the comet assay showed that DNA repair was triggered when DNA replication was inhibited after the treatment of 4-NQO, and the hPCNA transactivation seemed to contribute to DNA repair.	4-Nitroquinoline-1-oxide	172-177	proliferating cell nuclear antigen	Homo sapiens	187-192	
15474986-7	2005	Taken together, our data indicate that after 4-NQO treatment hPCNA is transactivated by Ser15 phosphorylated p53, and participate in DNA repair.	4-Nitroquinoline-1-oxide	45-50	proliferating cell nuclear antigen	Homo sapiens	61-66	
33873145-4	2021	We observed that in a 4-Nitroquinoline N-oxide (4NQO)-induced oral carcinogenesis model, tacrolimus treatment was associated with a significantly lower ratio of cancer formation (52.94% vs. 90%) and a lower proportion of Ki67 and proliferation cell nuclear antigen (PCNA) -positive cells in lesion areas (P < 0.001).	4-Nitroquinoline-1-oxide	22-46	proliferating cell nuclear antigen	Homo sapiens	230-271	
33873145-4	2021	We observed that in a 4-Nitroquinoline N-oxide (4NQO)-induced oral carcinogenesis model, tacrolimus treatment was associated with a significantly lower ratio of cancer formation (52.94% vs. 90%) and a lower proportion of Ki67 and proliferation cell nuclear antigen (PCNA) -positive cells in lesion areas (P < 0.001).	4-Nitroquinoline-1-oxide	48-52	proliferating cell nuclear antigen	Homo sapiens	230-271